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A B S T R A C T
Plants are vital source of compounds oﬀering plethora of therapeutic eﬀects against various ailments without much
side eﬀects. Due to wide spread prevalence and drug resistance in cancer; there is an urgent need for discovery of
new anti-cancer drugs. In the present study, selected novel anti-cancer plants derived compounds (cmpd1 to
cmpd15) from Himalayan region were docked with deﬁned molecular targets that regulate cell proliferation and
apoptosis. The binding energies of best docked compounds ranged between −8.0 kcal/mol and −11.71 kcal/mol.
Further analysis revealed critical hydrogen bonds and hydrophobic interactions between compounds and targets.
The best docked compounds viz., cmpd15 against cyclin-dependent kinase-2 (CDK-2), cmpd8 against CDK-6 and
cmpd9 against Topoisomerase I and II showed higher binding aﬃnities than the native co-crystal ligands. The root
mean square deviation (RMSD) and potential energy plot clearly indicates the stability of the complexes during 20 ns
molecular dynamics (MD) simulation. The Molecular Mechanics/Poisson Boltzmann Surface Area (MM/PBSA)
binding energy analysis revealed Van der Waals energy component which is the principal stabilizing energy for their
interactions except CDK-2/cmpd15 complex. The polar solvation energy did not have favorable contribution to their
stabilization. The binding energy decomposition analysis revealed per residue contribution for each docked
complexes. Physicochemical proﬁle studies showed that majority of the compounds conform to Lipinski's rule of
ﬁve (ROF) having low to high blood brain barrier (BBB) penetration, human intestinal absorption, plasma binding
protein inhibition and P glycoprotein inhibition.
1. Introduction
Cancer is the leading cause of deaths worldwide today, which have
aﬀected the lives of millions of people around the world. Eﬀorts have
been made towards development of new drugs for the prevention and
treatment of cancer. The major problem of cancer treatment is the
adverse eﬀects of chemotherapy drugs which have been reported to
have negative impact in our body and also suppression of the immune
system. Besides, the eﬀectiveness of chemotherapy is limited by drug
resistance [1,2]. There is an urgent need for new anti-cancer drugs and
therapies. Plant derived natural compounds have been in use against
various ailments since ancient period and has been regarded as
promising drugs against cancer without much of side-eﬀects. A total
of 26 plant derived drugs were approved/launched during 2000–2006
[3]. Alkaloids such as vinblastine isolated from Catharanthus roseus, is
commonly used to treat Hodgkin's lymphoma [4,5]. Camptothecin,
another monoterpene indole alkaloid isolated from certain angios-
perms have been eﬀective against recurrent colon cancer and its
cellular target is DNA topoisomerase I [6,7]. Paclitaxel, a diterpene
alkaloid isolated from Taxus brevifolia is eﬀective against breast and
ovarian cancer and acts by blocking depolymerization of microtubules
[8]. Etoposide, a semisynthetic derivative of podophyllotoxin, isolated
from roots of Podophyllum peltatum has been approved for lung
cancer, choriocarcinoma, ovarian cancer, lymphoma etc and its mode
of action is through inhibition of DNA topoisomerase II [8].
The rapid advancement of high throughput screening, structural
elucidation and combinatorial synthesis have revitalized the potential of
plant derived compounds as chemotherapeutic agents against cancer. For
developing any natural product for clinical application we need to
comprehensively understand and identify its molecular targets and mode
of action [9]. Computational screening programs such as molecular
docking has greatly helped in rapid screening of chemical entities against
their macromolecular targets [10–12]. Besides, in silico toxicity screens
have routinely been employed in drug discovery pipelines to study the
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Table 1
The dimensions of grid box from the center of bound ligands utilized for molecular docking studies.
Macromolecular
target
Co-crystal ligand Structure Grid box dimensions
No. of grid
points
(npts)
Center (xyz
coordinates)
Grid point
spacing (Å)
CDK-2 4-[3-Hydroxyanilino]-6,7-
Dimethoxyquinazoline (DTQ)
60×60×60 −7.623, 49.881,
11.367
0.375
CDK-6 3,7,3′,4′-Tetrahydroxyflavone (FSE) 60×60×60 2.296, 36.095,
138.519
0.375
Topoisomerase I 4-Ethyl-4-Hydroxy-1,12-Dihydro-4h-2-Oxa-
6,12a-Diaza-Dibenzo[B,H]Fluorene-3,13-Dione
(EHD)
70×70×70 21.171, −3.904,
25.952
0.375
Topoisomerase II Phosphoaminophosphonic Acid-Adenylate Ester
(ANP)
60×60×60 39.262, −1.072,
37.077
0.375
G-quaruplex 3-Pyrrolidin-1-Yl-N-[6-(3-Pyrrolidin-1-Yl-
Propionylamino)-Acridin-3-Yl]-Propionamide
(PYN)
45×45×60 15.456, 16.903,
7.206
0.375
Bcl-2 4-(4-Benzyl-4-Methoxypiperidin-1-Yl)-N-[(4-
{[1,1-Dimethyl-2-(Phenylthio)Ethyl]Amino}-3-
Nitrophenyl)Sulfonyl]Benzamide (LI0)
65×65×65 −0.024, 3.142,
−0.361
0.375
VEGFR-2 Methyl (5-{4-[({[2-Fluoro-5-(Trifluoromethyl)
Phenyl]Amino}Carbonyl)Amino]Phenoxy}-1h-
Benzimidazol-2-Yl)Carbamate (GIG)
70×70×70 5.396, 32.493,
15.884
0.375
(continued on next page)
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pharmacokinetic and pharmacodynamics properties of the selected drug-
like compounds before proceeding to experimental trials [13].
Recently, ﬁfteen novel Himalayan plant derived compounds have been
reported which display anti cancer properties [14]. The present study aims
at exploring the binding modes of these ﬁfteen compounds against nine
selected molecular targets- CDK-2, CDK-6, Topoisomerase I, DNA
Topoisomerase II, Telomere: G-quadruplex, Bcl-2, VEGFR-2, β-tubulin
and XIAP because of their essential role in regulating cellular proliferation
and apoptosis [15]. These 15 plant derived compounds belong to diﬀerent
classes of natural compounds. The binding modes of the docked
complexes were subjected to molecular dynamics (MD) simulation in
order to determine the stability of the system. MM/PBSA binding analysis
was performed to determine the driving energy component for molecular
interaction and binding per residue contribution. The physicochemical
properties of the compounds were determined to explore their bioavail-
ability and possible toxicities in humans.
2. Materials and methods
2.1. Structure modeling of active compounds
The structural information of the ﬁfteen selected compounds viz;
Acetylshikonin (cmpd1), 5,7,4′-Trimethoxyﬂavanone (cmpd2), 3-
(8′(Z),11′(Z)-pentadecadienyl)catechol (cmpd3), 3,5,6,7,8,3′,4′-hepta-
methoxyﬂavone (cmpd4), Chrysoplenetin (cmpd5), Chrysosplenol
(cmpd6), 1-phenyl-hepta-1,3,5-triyne (cmpd7), Asclepin (cmpd8),
12B-hydroxycalotropin (cmpd9), Solamargine (cmpd10), Taxiresinol
(cmpd11), Isotaxirenisol (cmpd12), Secoisolariciresinol (cmpd13), 2-
deacetoxytaxinine J (2-DAT-J) (cmpd14) and Asiatic acid (cmpd15)
reported to have anti-anticancer properties were retrieved from the
review literature [14]. The 2D structures of the ﬁfteen compounds were
modeled and converted to 3D structures using ACD/ChemSketch
version 12.01 software. These structures were then optimized using
MMFF force ﬁeld, using optimization parameters such as 500 steps of
steepest descent algorithm and convergence criterion of 10e-7 [16].
The optimized structures were used for molecular docking studies.
2.2. Molecular docking studies
The three dimensional structures of nine selected molecular targets
(receptors) involved in regulating cell proliferation and apoptosis-
CDK-2(PDB ID: 1DI8), CDK-6(PDB ID: 1XO2), Topoisomerase I
(PDB ID: 1T8I), Topoisomerase II (PDB ID: 1ZXM), G-Quadruplex
(PDB ID: 1L1H), Bcl-2(PDB ID: 2O2F), VEGFR-2 (PDB ID: 2OH4), β-
Tubulin (PDB ID: 4I4T) and XIAP-Bir2 (PDB ID: 4KJU) were obtained
from Protein Data Bank (PDB) (www.rcsb.org). Because of the absence
of β tubulin crystal structure in Homo sapiens we used Bos taurus
tubulin as it showed 100% identity with humans (Chain B of PDB ID:
Table 1 (continued)
Macromolecular
target
Co-crystal ligand Structure Grid box dimensions
No. of grid
points
(npts)
Center (xyz
coordinates)
Grid point
spacing (Å)
β-tubulin Guanosine -5′-Diphosphate (GDP) 50×50×50 14.662, 49.445,
18.869
0.375
XIAP-Bir2 N-{(3S)−5-(4-aminobenzoyl)-1-[(2-
methoxynaphthalen-1-yl)methyl]-2-oxo
−2,3,4,5-tetrahydro-1H-1,5-benzodiazepin-3-
yl}-N~2~-methyl-L-alaninamide (1RH)
50×50×50 29.799, 34.241,
11.358
0.375
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4I4T). The steps for preparation of receptors include (a) removal of
heteroatoms (water, ions), (b) addition of polar hydrogens, and (c)
assignment of Kollman charges. The active sites were deﬁned by
considering grid boxes of appropriate sizes around the bound co-
crystal ligands as shown in Table 1.
The ﬁfteen natural compounds were docked against nine molecular
targets using AutoDock4.2 software [17]. Docking experiment was
performed using Lamarckian Genetic Algorithm, with an initial popu-
lation of 250 randomly placed individuals, a maximum number of 106
energy evaluations, a mutation rate of 0.02, and a crossover rate of 0.8.
One hundred independent docking runs were performed for each
compound. Conformation clustering was done considering root mean
square deviation (RMSD) cut-oﬀ of 2.0 Å were cluster and the most
favorable conformation was represented by the lowest free energy of
binding (ΔG) and the lowest inhibition constant (Ki). The most
favorable binding conformation was selected and evaluated for mole-
cular interaction with their receptors using LigPlot+ version 1.4.5
software [18]. To ensure that the binding pose of the docked compound
represents favorable and valid potential binding mode, the docking
parameters and methods were validated by redocking the co-crystal
ligand against their respective targets.
2.3. Molecular dynamics studies
The trajectories of docked complexes were analyzed through 20 ns
of MD simulations using GROMACS 4.6.5 software package [19] with
GROMOS96 43a1 force ﬁeld for protein docked complexes and Amber
ﬀ99SB force ﬁeld for DNA docked complex. The complexes were
prepared for MD simulation through solvation within a water ﬁlled
3-D cube of 1 Å spacing using simple point charge (SPC216), a three-
point model for water. A leap-frog time integration algorithm was used
for integrating Newton's equations of motion. The systems were
neutralized and energy minimized. The temperature was set at 300 K
and the complexes were equilibrated for 100 ps in NVT (Number of
particles, Volume and Temperature) ensemble and another 100 ps in
NPT ensemble (Number of particles, Pressure and Temperature). After
heating and equilibration, the docked complexes were subjected to
production MD run for 20 ns in NPT ensemble. PRODRG web server
[20] and ACPYPE program [21] was used to generate topologies for
ligands compatible with GROMOS96 43a1 force ﬁeld and Amber
ﬀ99SB force ﬁeld respectively. The particulars of the docked complexes
used in MD simulation are enumerated in Table 2. Root mean square
deviation (RMSD) and potential energies of the docked complexes was
calculated using g_rms and g_energy programs respectively. The
graphs are generated using Origin 7.0 software and Xmgrace plotting
tools.
2.4. MM/PBSA binding energy analysis
The binding free energies of the docked complexes were computed
using g_mmpbsa tool of GROMACS software [22] based on the
molecular mechanics/Poisson–Boltzmann surface area (MM/PBSA)
method [23]. The binding energy of the target with the ligand in
solvent (ΔGbind) is calculated using equation (Eq. (1)):
G G G GΔ = −( + )bind complex target ligand (1)
where, Gcomplex is the total free energy of the target-ligand complex and
Gtarget and Gligand are total free energies of the target and ligand in
solvent, respectively.
The free energy for each individual component can be expressed by
equation (Eq. (2))
G = E −TS + GX MM Solv (2)
where, x is the target or ligand or target–ligand complex. EMM is the
average molecular mechanics potential energy in a vacuum. TS refers to
the entropic contribution to the free energy in a vacuum where T and S
denote the temperature and entropy, respectively. The last term GSolv
is the free energy of solvation.
The binding free energy calculations were performed for 1000
frames taken at an interval of 10 ps during the equilibrium phase of
each trajectory of MD simulation. The average binding energy was
computed by using bootstrap analysis method [22].
2.5. Physicochemical proﬁle of active compounds
The drug attrition is a serious problem at clinical stages of drug
development due to lack of suﬃcient pharmacokinetics and pharma-
codynamics studies. Various physico-chemical properties such as drug-
like properties and toxicity of the selected compounds were evaluated
using open source tools such as Molinspiration (http://www.molin-
spiration.com/), DataWarrior program version 3.12.1 software [24],
FAF Drugs3 (http://fafdrugs3.mti.univ-paris-diderot.fr/) and
PreADMET (https://preadmet.bmdrc.kr/).
3. Results and discussion
3.1. Molecular docking analysis
Before proceeding with docking of selected natural compounds, the
docking protocols and parameters were validated by redocking method.
The co-crystal ligands viz; DTQ, FSE, EHD, ANP, PYN, LI0, GIG, GDP
and 1RH were docked with their cognate molecular targets-CDK-2,
CDK-6, Topoisomerase I, Topoisomerase II, G-Quadruplex, Bcl-2,
VEGFR-2, β-tubulin and XIAP-Bir2 respectively. The root mean square
Table 2
Physico-chemical conditions set for Molecular dynamics simulation of nine docked complexes.
Docked complexes No. of residues/
Nucleotides
Total charge on
macromolecular targets
No. of water
molecules
Counter ions
added
Density
(Kg/m3)
Pressure
(bar)
Temperature (K)
CDK-2/cmpd15 283 6.000 e 19,932 6 Cl- ions 999.661 ±
0.17
0.931 ± 0.32 299.647 ± 0.27
CDK-6/cmpd8 289 −7.000 e 20,610 7 Na+ ions 999.358 ±
0.098
1.006 ± 0.17 299.72 ± 0.28
Topoisomerase I/
cmpd9
565 22.000 e 66,655 22 Cl- ions 992.761 ±
0.096
1.009 ± 0.075 299.667 ± 0.37
Topoisomerase II/
cmpd9
373 5.000 e 31,402 5 Cl- ions 997.745 ±
0.14
0.966 ± 0.36 299.666 ± 0.32
G-quaruplex/cmpd12 24 −22.000 e 4301 22 Na+ ions 1031.57 ±
0.43
1.164 ± 1.2 299.906 ± 0.13
Bcl-2/cmpd9 138 −5.000 e 9187 5 Na+ ions 1004.18 ±
0.29
1.287 ± 0.97 299.718 ± 0.2
VEGFR-2/cmpd9 299 2.000 e 19,950 2 Cl- ions 1003.1 ± 0.15 1.139 ± 0.37 299.707 ± 0.34
β-tubulin/cmpd4 420 −15.000 e 20,946 15 Na+ ions 1011.27 ± 0.1 0.890 ± 0.23 299.73 ± 0.26
XIAP-Bir2/cmpd9 82 1.000 e 8208 1 Cl- ions 996.698 ± 0.2 1.007 ± 0.36 299.716 ± 0.25
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deviation (RMSD) between the co-crystal and docked conformation
was found to be < 2 Å except in case of PYN, where it is slightly higher
than 2.0 Å (Fig. 1). The redocking results conﬁrmed that ligands were
bound to their targets very close to the true conformation indicating the
reliability of the docking protocols and parameters. Since these co-
crystal ligands except GDP are known inhibitor of their respective
targets, therefore, binding energies of each plant derived compounds
were compared with them to assess their diﬀerences in binding
aﬃnities. Fifteen anticancer plant derived compounds (Fig. 2) belong-
ing to diﬀerent classes such as Phenolics, Alkynes, Glycosides, Lignans
and Terpenes and nine molecular targets were used for the docking
studies. Each compound was docked against the macromolecular
targets and their binding energies and molecular interactions were
investigated in details. The binding energies of all the 15 compounds
and the co-crystal ligands are enumerated in Table 3. The molecular
interaction of the best docked compound against each target was
analyzed in detail..
3.1.1. Molecular interaction of cmpd15 with CDK-2
Cmpd15 was best docked with CDK-2 with binding energy of
−10.96 kcal/mol and inhibition constant of 9.24 nM. It interacts with
CDK-2 through four hydrogen bonds with Ile10, His84, Gln85, Leu298
and hydrophobic interactions with Ala31, Phe82, Leu83, Asp86, Lys89,
Gln131 and Leu134 (Fig. 3A). Previous report showed that extract of
Centella asiatica containing Cmpd15 as active compound exhibited 95%
inhibition against MCF-7 cell lines at concentration of 10 µg/ml [25] and
anti-proliferative eﬀects on multiple myeloma RPMI 8226 cells with IC50
values ranging from 53.76 to 24.88 µmol/l from 12 to 48 h respectively
[26]. In our molecular docking studies, cmpd15 exhibited better binding
energy and displayed stronger interaction with CDK-2 than co-crystal
ligand (DTQ). CDK-2 is a critical enzyme regulating the transition of cells
from G1 to S phase. The inhibition of this enzyme therefore, could lead to
arrest of cell proliferation in cancer conditions.
3.1.2. Molecular interaction of cmpd8 with CDK-6
Cmpd8 was identiﬁed as the best docked compound against CDK-6,
an enzyme which forms complex with cyclin D and controls the cell
cycle progression from G1 to S phase. Cmpd8 displayed binding energy
of −11.09 kcal/mol and inhibition constant of 7.48 nM. Its interaction
with CDK-6 was comparatively stronger than the co-crystal ligand
(FSE), and interacts through six hydrogen bonds with His100, Asp104,
Lys147, Asn150 and Asp163 and hydrophobic interactions with Ile19,
Gly20, Gly22, Val27, Val101, Asp102, Gln103, Gln149 and Leu152
(Fig. 3B). Earlier report showed that the isolated bioactive compound
cmpd8 from Asclepias curassavica showed IC50 of 0.02 mg/ml against
human hepatoma carcinoma cell line [27].
3.1.3. Molecular interaction of cmpd9 with Topoisomerase I,
Topoisomerase II, Bcl-2, VEGFR-2 and XIAP-Bir2
Interestingly, cmpd9 showed best interactions with ﬁve macromo-
lecular targets viz; Topoisomerase I, Topoisomerase II, Bcl-2, VEGFR-2
and XIAP-Bir2. It interacts with Topoisomerase I with binding energy
of −10.87 kcal/mol and inhibition constant of 10.69 nM. This interac-
tion was comparatively stronger than the co-crystal ligand, and
encompasses three hydrogen bonds through Lys425, Tyr426 and
Met428 and hydrophobic interactions via Ala351, Asn352, Ile427,
Leu429, Pro431, Lys436, Lys439 and Asp440 (Fig. 3C). Earlier report
showed that the isolated bioactive compound cmpd9 from Asclepias
curassavica showed IC50 of 0.69 mg/ml against human hepatoma
carcinoma cell line [27]. This compound showed strong interaction
with Topoisomerase I, an enzyme which cleaves one of the strands of
double stranded DNA and reanneals the strand. Cmpd9 interacts with
Topoisomerase II with binding energy of −11.71 kcal/mol and inhibi-
tion constant of 2.63 nM. Topoisomerase II cleave both the stands of
double stranded DNA to resolve supercoils This interaction was
comparatively stronger than the co-crystal ligand, and encompasses
ﬁve hydrogen bonds through Ser149, Arg162, Asn163 and Gly166 and
hydrophobic interactions via Asn91, Arg98, Ile125, Pro126, Ile141,
Thr147, Ser148, Asn150, Gly161, Gly164, Tyr165, Ala167 and Gln376
(Fig. 3D). Cmpd9 interacts with Bcl-2 with binding energy of
−9.46 kcal/mol and inhibition constant of 117.15 nM. B-cell lympho-
ma-2 (Bcl-2) belongs to Bcl-2 family which inhibits apoptosis. This
interaction was comparatively stronger than the co-crystal ligand, and
encompasses only hydrophobic interactions via Ala97, Asp100,
Phe101, Tyr105, Asp108, Phe109, Met112, Leu134, Gly142, Arg143,
Val145, Ala146 and Tyr199 (Fig. 3F). Cmpd9 interacts with VEGFR-2
with binding energy of −10.72 kcal/mol and inhibition constant of
13.76 nM. This interaction was comparatively stronger than the co-
Fig. 1. Validation of molecular docking results. The root mean square deviation (RMSD) was calculated between the original co-crystal position (purple) and docked poses (cyan) for the
co-crystal ligands DTQ through 1RH. (For interpretation of the references to color in this ﬁgure legend, the reader is referred to the web version of this article.).
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crystal ligand, and encompasses only hydrophobic interactions via
Leu838, Val846, Ala864, Lys866, Glu883, Leu887, Val897, Val914,
Glu915, Phe916, Cys917, Gly920, Leu1033, Cys1043, Asp1044 and
Phe1045 (Fig. 3G). Vascular endothelial growth factor receptor
(VEGFR) regulate homeostasis, blood and lymphatic vessel develop-
ment. Cmpd9 was also best docked with XIAP-Bir2 with binding
energy of −8.34 kcal/mol and inhibition constant of 773.40 nM. The
X-linked inhibitor of apoptosis protein (XIAP) belongs to IAP family
and strong inhibitor of the caspase. This interaction was comparatively
stronger than the co-crystal ligand, and encompasses two hydrogen
bonds through Lys206 and Lys208 and hydrophobic interactions via
Gln197, Leu207, Asn209, Trp210, Glu211, Asp214, Glu219, Arg222
and His223 (Fig. 3I).
3.1.4. Molecular interaction of cmpd12 with G-quadruplex DNA
G-quadruplex are DNA sequences containing simple guanine- rich
tandem repeats at the ends of eukaryotic chromosomes, which main-
tain genomic stability. Cmpd12 was best docked with G-quadruplex
with binding energy of −8.18 kcal/mol and inhibition constant of
1010 nM. This interaction was comparatively stronger than the co-
crystal ligand, and encompasses one hydrogen bond through Dg2012
and hydrophobic interactions via Dt1006, Dt1007, Dt1008, Dg1009
and Dg2011 (Fig. 3E). Isotaxirenisol (cmpd12) showed inhibition
against Caco-2 cell line at IC90 of 0.251 µg/ml [28].
3.1.5. Molecular interaction of cmpd4 with β-tubulin
Cmpd4 was best docked with β-tubulin with binding energy of
−10.87 kcal/mol and inhibition constant of 10.69 nM. β-tubulin is a
structural unit of microtubules that regulates cell growth and motility.
This interaction was comparatively stronger than the co-crystal ligand,
and encompasses three hydrogen bonds through Gln11 and Cys12 and
hydrophobic interactions via Ala9, Gly10, Asp69, Glu71, Gly98, Ala99,
Asn101, Ser140, Thr145, Gly146, Asp179, Asn206 and Tyr224
(Fig. 3H). The ethanolic extract of Citrus limon's fruit containing
3,5,6,7,8,3′,4′-heptamethoxyﬂavone displayed anticancer activity by
inhibiting HT-29 cell line at IC50 (5.9 µg/ml) [29] and 3,5,6,7,8,3′,4′-
heptamethoxyﬂavone extracted from peel of citrus plants exhibited
impressive anti-tumour properties on mouse skin papillomas induced
by ( ± )-(E)-methyl-2-[(E)-hydroxyimino]-5-nitro-6-methoxy-3-hexe-
namide (NOR1) [30].
3.2. Molecular dynamics simulation analysis
3.2.1. System stability of docked complexes
Each of the nine docked complexes obtained through molecular
docking was subjected to molecular dynamics simulation in order to
validate the binding modes of the ligands. The snapshots from 0 to
20 ns time frame trajectories of the docked complexes are represented
in Fig. 4 which shows the dynamic nature of the target and their bound
ligands. Root mean square deviation (RMSD) of Cα atoms of proteins
and backbone of G-quadruplex was calculated by superimposing the
MD production trajectories to their starting structures in order to
evaluate their backbone stability with time. The RMSD values of the
docked complexes ﬂuctuated with larger amplitude in the beginning
and seemed to remain virtually constant after 10 ns averaging at 0.275
± 0.012 nm, 0.261 ± 0.042 nm, 0.697 ± 0.048 nm, 0.339 ± 0.019 nm,
0.403 ± 0.014 nm, 0.331 ± 0.012 nm, 0.366 ± 0.018 nm, 0.251 ±
0.010, 0.261 ± 0.017 nm for CDK-2/cmpd15, G-quadruplex/cmpd12,
Topoisomerase I/cmpd9, CDK-6/cmpd8, Topoisomerase II/cmpd9,
Bcl-2/cmpd9, VEGFR-2/cmpd9, β-tubulin/cmpd4 and XIAP-Bir2/
cmpd9 respectively (Fig. 5). This conﬁrmed that the complexes had
achieved their structural convergence from 10 ns onwards and advo-
cates our choice for considering the time period of MD simulation till
20 ns for various analyses. Larger ﬂuctuation in amplitudes was found
for Topoisomerase I/cmpd9 and Topoisomerase II/cmpd9 docked
complexes compared to other complexes in this study. Our ﬁndings
corroborates with recent studies by Singh et al. [31] who has reported
higher RMSD value ranging from 0.69 to 0.7 nm for Topoisomerase I
complexed with topotecan (known inhibitor) and oliveroline (alkaloid)
and 0.49–0.52 nm for Topoisomerase II complexed with etoposide and
oliveroline which seemed to be due to higher ﬂexibility of the protein.
The energetics of the ﬂuctuations of the docked complexes was
assessed by monitoring their potential energies during the course of
MD simulation which showed steady values reconﬁrming the stability
of the docked complexes (Fig. 6). The average potential energies of the
docked complexes are −865.886 ± 0.767×103 kJ/mol, −209.563 ±
0.350×103 kJ/mol, −2871.333 ± 1.379×103 kJ/mol, −893.882 ±
0.775×103 kJ/mol, −1361.359 ± 0.960×103 kJ/mol, −403.658 ±
0.513×103 kJ/mol, −869.709 ± 0.753×103 kJ/mol, −930.065 ±
0.788×103 kJ/mol, −352.641 ± 0.490×103 kJ/mol for CDK-2/cmpd15,
G-quadruplex/cmpd12, Topoisomerase I/cmpd9, CDK-6/cmpd8,
Fig. 2. Chemical structure of ﬁfteen anticancer compounds selected for molecular docking studies belonging to diﬀerent classes- cmpd1-6 (Phenolics), cmpd7 (Alkyne), cmpd8-10
(Glycosides), cmpd11-13 (Lignans), cmpd14-15 (Terpenes).
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Topoisomerase II/cmpd9, Bcl-2/cmpd9, VEGFR-2/cmpd9, β-tubulin/
cmpd4 and XIAP-Bir2/cmpd9 respectively. The larger negative poten-
tial energies of Topoisomerase I and Topoisomerase II docked com-
plexes strongly corroborates with their higher RMSD values in our
studies, underlining the greater conformational ﬂexibilities of these
proteins.
3.2.2. Binding dree energy analysis
To characterize the strength of interaction of best docked ligands with
their targets, the binding free energies of the docked complexes were
calculated using MM/PBSA methodology considering a total of thousand
frames from the last 10 ns of MD production simulation trajectories as
shown in Table 4. The binding energies were decomposed into their
energy components viz; Van der Waals energy, electrostatic energy, polar
solvation energy and SASA non-polar solvation energy to get insights into
their individual contributions. In all the docked complexes, the principle
driving component of binding being Van der Waals energy except in case
of CDK-2/cmpd15 complex, where electrostatic energy component played
vital in strengthening the binding mode. The polar solvation energy did
not have favorable contribution to the total interaction in all the docked
complexes and SASA non-polar solvation energy contribute signiﬁcantly
to their overall binding energies except CDK-2/cmpd15, which may be
explained by their decreased Van der Waals energy value due to nonpolar
amino acids. Contrary to molecular docking results, the binding mode of
cmpd9 did not show favorable interaction with Bcl-2 which may be
attributed to decrease contribution by Van der Waals energy, electrostatic
energy and SASA non-polar solvation energy.
3.2.3. Residue wise contribution analysis of the docked complexes
The binding energies of the docked complexes were decomposed to
explore residue wise contribution to the binding energy (Fig. 7 and
Table 5). In the CDK-2/cmpd15 complex, the residues dominantly
contributing to the binding energy include Arg214, Arg217, Lys237,
Arg200, Lys242, Arg169, Arg245, Arg199, Arg274, Lys178 and Lys88.
These contributing polar charged residues substantiates that electro-
static energy component is the driving component of interaction of
cmpd15 with CDK-2.
In the CDK-6/cmpd8, residues contributing signiﬁcantly to the
binding energy include Ile19, Glu61, Leu152, Asn150, Asp102, Gln149
and Glu99. The residues Ile19, Leu152, Asn150, Asp102 and Gln149
besides higher contribution are also involved in molecular interaction
with cmpd8 as revealed by our molecular docking results.
In the Topoisomerase I/cmpd9, residues contributing to the bind-
ing energy include Lys443, Lys439, Met428, Lys425 and Pro431. The
residues Lys439, Met428, Lys425 and Pro431 also are involved in
molecular interaction with cmpd9 corroborating with the molecular
docking results.
In the Topoisomerase II/cmpd9, residues contributing to the
binding energy include Ser149, Ile141, Arg162, Ile125 and Val137.
The residues Ser149, Ile141, Arg162 and Ile125 are also involved in
molecular interaction with cmpd9 which is in agreement with mole-
cular docking results.
In the G-quadruplex/cmpd12 complex, nucleotides contributing to
the binding energy include Dt1007, Dg2012, Dg1009, Dt1008, Dg2011,
Dt1006 and Dg1010. The nucleotides Dt1007, Dg2012, Dg1009,
Dt1008, Dg2011, Dt1006 and Dg1010 are also involved in molecular
interaction with cmpd12.
In the Bcl-2/cmpd9 complex, residues contributing to the binding
energy include Tyr199, Tyr105, Phe101, Leu198 and Asp100. The
residues Tyr199, Tyr105, Phe101 and Asp100 are also involved in
molecular interaction with cmpd9.
In the VEGFR-2/cmpd9complex, residues contributing to binding
energy include Phe1045, Phe916, Leu838, Tyr1057, Val914, Cys1043,
Val897, Leu1033 and Phe919. The residues Phe1045, Phe916, Leu838,
Val914, Cys1043, Val897 and Leu1033 are also involved in molecular
interaction with cmpd9.Ta
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Fig. 3. LigPlot+ results for molecular interaction of best docked ligands (purple ball and stick) with their molecular targets (A) CDK-2 (B) CDK-6 (C) Topoisomerase I (D)
Topoisomerase II (E) G-quadruplex (F) Bcl-2 (G) VEGFR-2 (H) β-tubulin (I) XIAP-Bir2. The green dashed line indicates hydrogen bond with the labeled distance. The arcs with spikes
radiating out corresponds to residues involved in hydrophobic interactions.
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sn02sn51sn01sn5sn0emiT/metsyS
CDK-2/cmpd15 
CDK-6/cmpd8 
Topoisomerase I/cmpd9
Topoisomerase II/cmpd9
G-quadruplex/cmpd12 
Bcl-2/cmpd9 
VEGFR-2/cmpd9 
β-tubulin/cmpd4 
XIAP-Bir2/cmpd9 
Fig. 4. The snapshots of trajectories of the docked complexes from 0 to 20 ns MD simulation. The protein targets are displayed in ribbon (orange: helix, cyan: sheet, grey: loops), G-
quadruplex in strands (tan: backbone, blue: nucleotides) complexed with the best docked ligands in spheres. (For interpretation of the references to color in this ﬁgure legend, the reader
is referred to the web version of this article.).
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In the β-tubulin/cmpd4 complex, residues contributing to binding
energy include Tyr224, Gly142, Cys12, Gly143 and Gln11. The residues
Tyr224, Cys12 and Gln11 are also involved in molecular interaction
with cmpd9 as indicated before by molecular docking results.
In the XIAP-Bir2/cmpd9 complex, residues contributing to the
binding energy include Asn209, Phe224, Lys208, Leu207 and His223.
Interestingly, Asn209, Lys208, Leu207 and His223 are also residues
involved in interaction with cmpd9 as revealed by molecular docking
studies.
3.3. Analysis of physicochemical properties
The physicochemical properties and ADMET properties of ﬁfteen
compounds were analyzed using various in silico tools realizing the
drug attrition rate at later stages of drug development process. The
Molinspiration results show that out of ﬁfteen natural compounds
selected in our studies, ﬁve compounds did not conform to Lipinski's
rule of ﬁve and exhibit various degrees of violations (Table 6).
Lipinski's rule of ﬁve (ROF) [32] is a rule of thumb in pharmaceutical
science to evaluate the druglikeness and their oral bioavailability in
humans based on some criteria- Molecular weight (MW) < 500,
compound's lipophilicity expressed as logP (partition coeﬃcient be-
tween n-octanol and water) < 5, number of groups in the molecule that
can donate hydrogen atoms to form hydrogen bonds (HBD) < 5 and
number of groups in the molecule which can accept hydrogen atoms to
form hydrogen bonds (HBA) < 10. Compounds -Cmpd3, Cmpd8 and
Cmpd9 showed one violation as their LogP and MW were higher than
the acceptable range which indicates that Cmpd 3 is highly lipophilic
and therefore, may have poor absorption rate. Cmpd 8 and Cmpd9
owing their large molecular weights may limit their diﬀusion across the
biological membranes. Cmpd14 showed two violations with its LogP
and MW not within the permissible limit and therefore, may have poor
absorption and slow diﬀusion across the lipid bilayer. Cmpd10 showed
the highest degree of violations with 3 violations in its MW, HBA and
HBD not within the acceptable range and this may severely limit its
diﬀusion owing to its large molecular weight. This could also aﬀect its
permeability due to its greater number of hydrogen bond donor and
acceptor groups.
Careful examination of the pharmacokinetic properties of drug-like
compounds such as Adsorption, Distribution, Metabolism and
Excretion (ADME) in humans can also limit the chance of failures in
clinical phases. For this, some physicochemical properties such as polar
surface area (sum of surface area of nitrogen and oxygen plus hydrogen
atoms attached to heteroatoms) (PSA < 140 Å2), rotatable bonds (RB
< 10), aqueous solubility at 25° and pH=7.5 (LogS > −4.0),
Duglikeness, mutagenicity, Tumorigenicity, reproductive eﬀective was
evaluated using DataWarrior program (Table 7). The DataWarrior
results showed six compounds (Cmpd3, Cmpd7, Cmpd8, Cmpd10,
Cmpd14 and Cmpd15) possess LogS value out of the acceptable range,
which indicates that these compounds will have low aqueous solubility
which in turn will aﬀect their distribution characteristics. Compound
cmpd3 and cmpd14 have rotatable bonds out of the acceptable range
which indicates their poor oral bioavailability. Compounds-cmpd9 and
cmpd10 have PSA values out of the permissible limit which implies that
they may have poor oral bioavailability. The druglikeness score of
majority of the compounds have negative score and only three
compounds (cmpd4, cmpd6 and cmpd10) possess positive score.
Compounds-cmpd 4, cmpd6 and cmpd10 therefore, possess molecular
fragments typically present in the marketed drugs. The majority of the
compounds except cmpd3, cmpd7 and cmpd14 are non-mutagenic,
non-tumorigenic, non irritant and without side eﬀects on the repro-
ductive health. Compounds-cmpd3, cmpd7 and cmpd14 showed high
irritant, high tumorigenicity and high irritancy respectively.
Other physicochemical properties of the compounds such as oral
bioavailability were evaluated using VEBER rule (a compound possess
good oral bioavailability if ≤10 RB and PSA≤140 Å2) and EGAN rule
(good orally available compounds have −1≤LogP≤5.8, PSA≤130 Å2),
Phospholipidosis and Fsp3 (deﬁnes molecular complexity, number of
sp3 hybridized carbons/total carbon count). The FAF3 drugs results
showed all the compounds have good bioavailability conforming to
both VEBER as well as EGAN rule (Table 8). All compounds except
Fig. 5. The root mean square deviation (RMSD) vs time plot for the trajectories of the
nine docked complexes.
Fig. 6. The potential energy vs time plot for the trajectories of the nine docked
complexes.
Table 4
MM/PBSA binding free energies (KJ/mol) and their energy components for docked complexes calculated during the equilibration period.
Systems Van der Waals energy
(kJ/mol)
Electrostatic energy (kJ/
mol)
Polar solvation energy
(kJ/mol)
SASA energy (kJ/
mol)
Binding free energy
(kJ/mol)
CDK-2/cmpd15 −0.004 ± 0.000 −57.472 ± 0.155 25.427 ± 1.751 0.085 ± 0.099 −31.949 ± 1.645
CDK-6/cmpd8 −233.213 ± 0.696 −81.831 ± 0.905 201.767 ± 1.041 −19.542 ± 0.036 −132.852 ± 0.783
Topoisomerase I/cmpd9 −162.967 ± 0.453 −109.155 ± 1.268 210.465 ± 1.971 −14.063 ± 0.032 −75.686 ± 0.811
Topoisomerase II/cmpd9 −245.002 ± 0.544 −216.552 ± 0.962 401.463 ± 1.643 −20.288 ± 0.040 −80.373 ± 0.911
G-quadruplex/cmpd12 −186.012 ± 0.837 −46.799 ± 0.922 80.496 ± 0.904 −16.122 ± 0.035 −168.411 ± 0.935
Bcl-2/cmpd9 −22.064 ± 1.514 −16.906 ± 1.104 40.005 ± 1.824 −1.940 ± 0.150 −0.840 ± 1.172
VEGFR-2/cmpd9 −252.638 ± 0.477 −172.578 ± 0.950 328.935 ± 1.514 −20.605 ± 0.035 −116.953 ± 0.718
β-tubulin/cmpd4 −271.204 ± 0.389 −33.721 ± 0.228 116.170 ± 0.414 −19.065 ± 0.029 −207.842 ± 0.417
XIAP-Bir2/cmpd9 −155.453 ± 1.043 −108.967 ± 0.951 161.153 ± 1.514 −11.920 ± 0.065 −115.158 ± 1.308
A.B. Gurung et al. Informatics in Medicine Unlocked 5 (2016) 1–14
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cmpd10 are non inducer of phospholipidosis. The compounds -cmpd3,
cmpd8, cmpd9, cmpd10, cmpd14 and cmpd15 have impressive Fsp3
value which may correlate to their good solubility.
PreADME was also used to assess ADMET properties such as,
blood brain barrier penetration, human intestinal absorption,
CYP_2C19_inhibition, Pgb inhibition and Plasma protein binding
Fig. 7. MM/PBSA binding free energy contribution on a per residue/ nucleotide basis for each docked complexes.
A.B. Gurung et al. Informatics in Medicine Unlocked 5 (2016) 1–14
11
based on given criteria (Table 9). Drugs in vivo can either bind
reversibly to proteins and lipids in plasma known as Plasma protein
binding, which is used to monitor drug concentration in clinical trials
and predict their therapeutic dose. Plasma protein binding analysis was
carried out based on the criteria- a) Chemicals strongly bound with a
score more than 90% and b) chemicals weakly bound with a score less
than 90%. Our results showed that cmpd3, cmpd7, cmpd12, cmpd14
and cmpd15 are strongly bound to plasma protein binding. Blood-
brain barrier (BBB) form a highly selective barrier between the brain
and the rest of the body and drugs that target central nervous system
Table 5
The binding free energy contribution per residue wise of nine docked complexes. The figures in parentheses indicate binding energy contribution (kJ/mol).
Complexes Binding free energy contribution per residue wise
CDK-2/cmpd15 Arg214 (−6.418 ± 0.029), Arg217 (−6.407 ± 0.032), Lys237 (−6.215 ± 0.062), Arg200 (−5.707 ± 0.025), Lys242 (−5.498 ± 0.065), Arg169 (−5.202 ±
0.025), Arg245 (−5.136 ± 0.023), Arg199 (−5.095 ± 0.025), Arg274 (−5.056 ± 0.015), Lys178 (−5.029 ± 0.066) and Lys88 (−5.025 ± 0.053)
CDK-6/cmpd8 Ile19 (−13.972 ± 0.072), Glu61 (−7.512 ± 0.087), Leu152 (−7.185 ± 0.059), Asn150 (−5.768 ± 0.064), Asp102 (−5.687 ± 0.078), Gln149 (−5.471 ±
0.076) and Glu99 (−5.048 ± 0.038)
Topoisomerase I/cmpd9 Lys443 (−12.498 ± 0.203), Lys439 (−11.487 ± 0.261), Met428 (−6.355 ± 0.078), Lys425 (−5.712 ± 0.113) and Pro431 (−5.257 ± 0.047)
Topoisomerase II/cmpd9 Ser149 (−8.684 ± 0.117), Ile141 (−7.953 ± 0.038), Arg162 (−7.187 ± 0.059), Ile125 (−6.587 ± 0.036) and Val137 (−5.286 ± 0.037)
G-quadruplex/cmpd12 Dt1007 (−25.171 ± 0.126), Dg2012 (−15.050 ± 0.136), Dg1009 (−11.262 ± 0.192), Dt1008 (−8.928 ± 0.114), Dg2011 (−8.904 ± 0.069), Dt1006
(−8.385 ± 0.131) and Dg1010 (−6.507 ± 0.069)
Bcl-2/cmpd9 Tyr199 (−2.551 ± 0.180), Tyr105 (−1.928 ± 0.160), Phe101 (−1.030 ± 0.072), Leu198 (−0.469 ± 0.046), Asp100 (−0.429 ± 0.040)
VEGFR-2/cmpd9 Phe1045 (−13.630 ± 0.067), Phe916 (−8.146 ± 0.048), Leu838 (−7.452 ± 0.064), Tyr1057 (−6.547 ± 0.160), Val914 (−5.776 ± 0.036), Cys1043
(−5.75 ± 0.048), Val897 (−5.727 ± 0.034), Leu1033 (−5.392 ± 0.043) and Phe919 (−5.302 ± 0.095)
β-tubulin/cmpd4 Tyr224 (−8.373 ± 0.095), Gly142 (−8.006 ± 0.061), Cys12 (−7.724 ± 0.063), Gly143 (−7.061 ± 0.043) and Gln11 (−6.068 ± 0.059)
XIAP-Bir2/cmpd9 Asn209 (−8.393 ± 0.116), Phe224 (−8.29 ± 0.092), Lys208 (−6.88 ± 0.237), Leu207 (−6.157 ± 0.047) and His223 (−5.955 ± 0.099)
Table 6
Physicochemical properties of selected plant derived compounds calculated using Molinspiration.
Compounds Name LogPa MWb HBAc HBDd nviolationse
Cmpd1 acetylshikonin 2.26 316.31 6 2 0
Cmpd2 5,7,4′-Trimethoxyflavanone 3.26 314.34 5 0 0
Cmpd3 3-(8′(Z),11′(Z)-pentadecadienyl)catechol 7.38 316.49 2 2 1
Cmpd4 3,5,6,7,8,3′,4′-heptamethoxyflavone 3.35 432.43 9 0 0
Cmpd5 Chrysoplenetin 2.59 374.35 8 2 0
Cmpd6 Chrysosplenol 2.28 360.32 8 3 0
Cmpd7 1-phenyl-hepta-1,3,5-triyne 3.71 164.21 0 0 0
Cmpd8 Asclepin 1.85 574.67 10 2 1
Cmpd9 12B-hydroxycalotropin 0.23 548.63 10 4 1
Cmpd10 Solamargine 2.41 868.07 16 9 3
Cmpd11 Taxiresinol 2.02 346.38 6 4 0
Cmpd12 Isotaxirenisol 1.32 346.38 6 5 0
Cmpd13 Secoisolariciresinol 2.08 362.42 6 4 0
Cmpd14 2-deacetoxytaxinine J (2-DAT-J) 7.25 650.76 10 0 2
Cmpd15 Asiatic acid 4.7 488.71 5 4 0
a Partition coeﬃcient between n-octanol and water.
b Molecular weight.
c Hydrogen bond acceptor.
d Hydrogen bond donor.
e Number of ROF violations.
Table 7
Physicochemical properties of selected plant derived compounds calculated using DataWarrior.
Compounds cLogSa PSA (Å2)b RBc Druglikeness Mutagenic Tumorigenic Reproductive Eﬀective Irritant
Cmpd1 −1.898 100.9 6 −2.3149 low low none none
Cmpd2 −3.582 53.99 4 −0.13101 none none none none
Cmpd3 −4.581 40.46 12 −14.789 none none none high
Cmpd4 −3.83 94.82 9 1.6253 none none none none
Cmpd5 −3.184 107.59 6 −0.54261 none none none none
Cmpd6 −2.87 118.59 5 0.21649 none none none none
Cmpd7 −7.283 0 3 −7.4721 none high none none
Cmpd8 −4.757 137.82 4 −2.4127 none none none none
Cmpd9 −3.948 151.98 2 −2.5188 none none none none
Cmpd10 −5.557 238.48 7 3.1642 none none low none
Cmpd11 −2.163 99.38 5 −0.47393 none none none none
Cmpd12 −2.293 110.38 4 −3.9043 none none none none
Cmpd13 −2.544 99.38 9 −3.9043 none none none none
Cmpd14 −6.344 131.5 12 −5.1523 none none none high
Cmpd15 −5.205 97.99 2 −5.9983 none none none none
a Aqueous solubility at 25° and pH=7.5.
b Polar surface area.
c Rotatable bonds.
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(CNS) should have better BBB penetration and drugs that target
peripheral organs should have low BBB penetration to minimize side
eﬀects to CNS Blood brain barrier penetration were based on the
following criteria a) High absorption to CNS for BB > 2.0 b) Middle
absorption to CNS for BB between 2.0 and 0.1 c) low absorption to CNS
for BB < 0.1 and the results showed that cmpd2, cmpd3 and cmpd7
may have high absorption to CNS. The prediction of human intestinal
absorption (HIA) play important role in design, optimization and
selection of oral drugs and was evaluated based on the following
criteria a) Poorly absorbed compounds for HIA between 0% and 20% b)
Moderately absorbed compounds for HIA between 20% and 70% and c)
well absorbed compounds for HIA between 70% and 100%. All the
compounds have well human intestinal absorption and compd10 is
moderately absorbed. Majority of the compounds except cmpd8,
cmpd9, cmpd10, cmpd15 were found to inhibitor of CYP_2C19, a
Cytochrome P450 (CYP) enzyme, responsible for metabolism of known
drugs in humans. It was also revealed that most of the compounds
except cmpd3, cmpd4, cmpd8, cmpd10, cmpd14, cmpd15 were found
to be non-inhibitor of P-glycoprotein (Pgb). P-glycoprotein is a
member of ATP-binding cassette superfamily of membrane transport
proteins responsible for eﬄux of many drugs and is a major component
of BBB.
Thus, the physicochemical proﬁle study showed that the best
docked compounds- cmpd4, cmpd12 and cmpd15 do not violate ROF
except cmpd8 and cmpd9 which showed only one ROF violation, which
is acceptable for oral bioavailability. Besides conforming to ROF, they
also seem to be non-mutagenic, non-irritant, non-tumorigenic and
without any adverse eﬀects on the reproductive eﬀect. They also seem
to have good oral bioavailability, non inducer of phospholipidosis, least
BBB penetrability and well human intestinal absorption. They are likely
to be non CYP_2C19 inhibitor except for compounds-cmpd4 and
cmpd12. But, they were found to be Pgp inhibitor except cmpd9 and
cmpd12. Except for cmpd12 and cmpd15, others are likely to be weakly
bound to plasma proteins. However, these physicochemical properties
can be improved by structural modiﬁcations using structure activity
relationship approach.
4. Conclusion
Realizing the potential of plant derived compounds to develop as
drugs against cancer, information on novel anti-cancer compounds
from Himalayan region were retrieved from literature. The chemical
structures of ﬁfteen such anti-cancer compounds were modeled and
optimized and their binding patterns were explored against nine
selected molecular targets implicated in cell proliferation and apopto-
sis, which provided insights into their molecular mechanism of
inhibition. Molecular docking results revealed their binding modes
with the targets through hydrogen bond and hydrophobic interactions.
The compounds which showed strong interaction with their respective
target includes- cmpd15 against CDK-2, cmpd8 against CDK-6, cmpd9
against Topoisomerase I, Topoisomerase II, Bcl-2, VEGFR-2 and
XIPA-Bir2, cmpd12 against G-Quadruplex DNA and cmpd4 against
β-tubulin. The best docked compounds against each target showed
stability in terms of RMSD and potential energy during the entire
course of molecular dynamic simulation and MM/PBSA analysis
revealed Van der Waals energy as the principal stabilizing energy
component of the complexes. The binding energy per residue/nucleo-
tide contribution revealed critical residues/nucleotides contributing
signiﬁcantly to the total binding energy. Physico-chemical proﬁling of
the compounds showed that majority of them have acceptable physi-
cochemical properties conforming to ROF and exhibited low to high
BBB penetration, Human intestinal absorption, Plasma binding protein
and P glycoprotein inhibition. The present study has great relevance in
area of rational drug design such as target ﬁshing for novel compounds
and drug optimization for improving their target selectivity and oral
bioavailability.
Table 8
Drug-like properties of selected natural compounds calculated using FAF Drugs3.
Compounds Oral
bioavailability
(VEBER)
Oral
bioavailability
(EGAN)
Phospho-
lipidosis
Fsp3a
Cmpd1 Good Good NonInducer 0.24
Cmpd2 Good Good NonInducer 0.28
Cmpd3 Good Good NonInducer 0.52
Cmpd4 Good Good NonInducer 0.32
Cmpd5 Good Good NonInducer 0.21
Cmpd6 Good Good NonInducer 0.17
Cmpd7 Good Good NonInducer 0.08
Cmpd8 Good Good NonInducer 0.84
Cmpd9 Good Good NonInducer 0.86
Cmpd10 Good Good Inducer 0.96
Cmpd11 Good Good NonInducer 0.37
Cmpd12 Good Good NonInducer 0.37
Cmpd13 Good Good NonInducer 0.4
Cmpd14 Good Good NonInducer 0.54
Cmpd15 Good Good NonInducer 0.9
a Number of sp3 hybridized carbons/total carbon count
Table 9
Adsorption, Distribution Metabolism Excretion and Toxicity (ADMET) properties of selected plant derived compounds calculated using PreADMET.
Compounds BBBa HIAb CYP_2C19_inhibitionc Pgp_inhibitiond Plasma_Protein_Binding
Cmpd1 0.063 90.239 Inhibitor Non 87.659
Cmpd2 1.240 98.069 Inhibitor Non 89.692
Cmpd3 14.716 93.527 Inhibitor Inhibitor 100
Cmpd4 0.069 98.954 Inhibitor Inhibitor 75.996
Cmpd5 0.015 93.076 Inhibitor Non 78.126
Cmpd6 0.040 86.802 Inhibitor Non 78.556
Cmpd7 3.552 100 Inhibitor Non 100
Cmpd8 0.015 89.322 Non Inhibitor 76.883
Cmpd9 0.039 71.437 Non Non 49.998
Cmpd10 0.036 23.394 Non Inhibitor 36.766
Cmpd11 0.315 83.048 Inhibitor Non 87.496
Cmpd12 0.101 73.963 Inhibitor Non 89.916
Cmpd13 0.398 84.137 Inhibitor Non 87.816
Cmpd14 0.351 99.748 Inhibitor Inhibitor 90.727
Cmpd15 0.628 91.239 Non Inhibitor 96.455
a Brain barrier penetration.
b Human intestinal absorption.
c Cytochrome P450 (CYP) enzyme.
d P-glycoprotein inhibition.
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